PP
NBRV

Paloma Partners’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Paloma Partners’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-149
Closed -$54K – 2053
2018
Q4 		$54K Buy
+149
New +$80.1K ﹤0.01% 1163

Other funds holding NBRV

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Paloma Partners's NBRV Position: Q1 2019 in Review

Paloma Partners sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q1 2019, closing a stake of 149 shares — an estimated $54K sold.

Paloma Partners first reported a position in NBRV in Q4 2018 and held it in 1 quarter. The position peaked at $54K in Q4 2018. 39 funds tracked by Wall St. Rank hold NBRV as of Q1 2019.

  • Paloma Partners reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q1 2019 after selling out during the quarter.
  • Paloma Partners sold 149 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q1 2019, an estimated $54K.
  • Paloma Partners first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2018 and held it in 1 quarter.
  • Paloma Partners's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $54K in Q4 2018.
  • 39 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q1 2019.

Based on Paloma Partners's 13F filing for Q1 2019, filed 15 May 2019.